Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
22.07
+0.49 (2.27%)
At close: Mar 6, 2026, 4:00 PM EST
22.39
+0.32 (1.45%)
After-hours: Mar 6, 2026, 5:22 PM EST
Syndax Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 172.35 | 23.68 | - | - | 139.71 | |
| Revenue Growth (YoY) | 627.84% | - | - | - | 9109.56% | |
| Cost of Revenue | 265.75 | 242.47 | 163.03 | 118.5 | - | |
| Gross Profit | -93.4 | -218.79 | -163.03 | -118.5 | 139.71 | |
| Selling, General & Admin | 180.08 | 121.18 | 66.92 | 33.26 | 25.24 | |
| Research & Development | - | - | - | - | 88.25 | |
| Operating Expenses | 180.08 | 121.18 | 66.92 | 33.26 | 113.49 | |
| Operating Income | -273.48 | -339.97 | -229.95 | -151.76 | 26.22 | |
| Interest Expense | -33.79 | -4.93 | -0.21 | -3.14 | -1.9 | |
| Interest & Investment Income | 22.73 | 26.09 | 21.16 | 5.87 | 0.4 | |
| Other Non Operating Income (Expenses) | -1.28 | -0.25 | -0.36 | -0.32 | 0.2 | |
| Pretax Income | -285.82 | -319.06 | -209.36 | -149.34 | 24.93 | |
| Income Tax Expense | -0.4 | -0.3 | - | - | - | |
| Net Income | -285.42 | -318.76 | -209.36 | -149.34 | 24.93 | |
| Net Income to Common | -285.42 | -318.76 | -209.36 | -149.34 | 24.93 | |
| Shares Outstanding (Basic) | 87 | 86 | 70 | 61 | 52 | |
| Shares Outstanding (Diluted) | 87 | 86 | 70 | 61 | 54 | |
| Shares Change (YoY) | 1.17% | 21.67% | 15.82% | 13.31% | 29.81% | |
| EPS (Basic) | -3.29 | -3.72 | -2.98 | -2.46 | 0.48 | |
| EPS (Diluted) | -3.29 | -3.72 | -2.98 | -2.46 | 0.46 | |
| Free Cash Flow | -323.17 | -274.9 | -160.6 | -133.68 | 29 | |
| Free Cash Flow Per Share | -3.73 | -3.21 | -2.28 | -2.20 | 0.54 | |
| Gross Margin | -54.19% | - | - | - | 100.00% | |
| Operating Margin | -158.68% | -1435.69% | - | - | 18.77% | |
| Profit Margin | -165.60% | -1346.11% | - | - | 17.84% | |
| Free Cash Flow Margin | -187.50% | -1160.91% | - | - | 20.76% | |
| EBITDA | -273.48 | -339.96 | -229.94 | -151.72 | 26.26 | |
| EBITDA Margin | -158.67% | - | - | - | 18.80% | |
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.03 | 0.04 | |
| EBIT | -273.48 | -339.97 | -229.95 | -151.76 | 26.22 | |
| EBIT Margin | -158.68% | - | - | - | 18.77% | |
| Revenue as Reported | 172.35 | 23.68 | - | - | 139.71 | |
| Advertising Expenses | 14.4 | 7.3 | 6.1 | 1.5 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.